Damietta Dermatology and Leprosy Hospital, Ministry of Health and Population, Damietta, Egypt.
Dermatology, Venereology and Andrology, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
J Cosmet Dermatol. 2022 Nov;21(11):6302-6307. doi: 10.1111/jocd.15262. Epub 2022 Aug 22.
Psoriasis (PsO) is a systemic autoimmune disease. Many pro-inflammatory and anti-inflammatory biomarkers have been associated with the pathogenetic process of psoriasis. IL-35 act as an anti-inflammatory cytokine through downregulation of TH-17 cell development and cytokine production. So, IL-35 might be utilized as potential future therapeutic agent for psoriasis.
To investigate the association between inflammatory (IL-17, TNF-α, IFN-γ) and anti-inflammatory cytokines (IL-35, TGF-β) in psoriasis patients.
A case-control study enrolled two groups: (Group I: 40 patients with psoriasis) and (Group II: 40 healthy age and sex-matched subjects). Full history was taken from all cases along with full dermatologic examination. The assessment of psoriasis severity was conducted by using PASI score. Assessment of inflammatory (IL-17, TNF-α, IFN-γ) and anti-inflammatory cytokines (IL-35, TGF-β) was performed by using ELISA technique.
There was a statistically significant increase of mean level of TNF-α, IL-17, and IFN-γ among psoriasis cases in comparison with controls. The mean level of TGF-β and IL-35 was statistically significantly reduced among the psoriasis cases in comparison with controls. TNF-α, IL-17, and IFN-γ showed a significant strong positive association in between and statistically significant strong negative relationship with IL-35 and TGF-β.
IL-35 has a significant role in the pathogenetic process of PsO, and it serves as a potential future therapeutic agent for psoriasis. The current results could be used as a clue for the utilization of inflammatory (IL-17, TNF-α, IFN-γ) versus anti-inflammatory cytokines (IL-35, TGF-β) in psoriasis patients as a diagnostic biomarker for severity of cases with psoriasis.
银屑病（PsO）是一种系统性自身免疫性疾病。许多促炎和抗炎生物标志物与银屑病的发病机制有关。IL-35 通过下调 TH-17 细胞的发育和细胞因子的产生来发挥抗炎细胞因子的作用。因此，IL-35 可能被用作银屑病的潜在未来治疗剂。
研究银屑病患者中炎症（IL-17、TNF-α、IFN-γ）和抗炎细胞因子（IL-35、TGF-β）之间的关系。
一项病例对照研究纳入了两组患者：（I 组：40 例银屑病患者）和（II 组：40 例年龄和性别匹配的健康对照）。对所有病例进行了详细的病史采集和全面的皮肤科检查。采用 PASI 评分评估银屑病的严重程度。采用 ELISA 技术检测炎症（IL-17、TNF-α、IFN-γ）和抗炎细胞因子（IL-35、TGF-β）的水平。
与对照组相比，银屑病患者的 TNF-α、IL-17 和 IFN-γ 的平均水平均有统计学显著升高。与对照组相比，银屑病患者的 TGF-β 和 IL-35 的平均水平显著降低。TNF-α、IL-17 和 IFN-γ 之间呈显著正相关，与 IL-35 和 TGF-β 之间呈显著负相关。
IL-35 在 PsO 的发病机制中具有重要作用，可作为银屑病的潜在未来治疗剂。目前的结果可作为在银屑病患者中利用炎症（IL-17、TNF-α、IFN-γ）与抗炎细胞因子（IL-35、TGF-β）的线索，作为银屑病患者严重程度的诊断生物标志物。
